Archive for April 22nd, 2008

Men Should Take Preventive Steps In Their Health Care

April 22nd, 2008 | Category: Uncategorized

The U.S. Department of soundness and Human Services’ Agency for Healthcare exploration and Quality (AHRQ) joined with The Advertising Council today to launch a national public service campaign designed to raise awareness among middle-aged men about the consequence of preventive medical testing.

Men are 25 percent less likable than women to have visited the doctor within the past year and are 38 percent more likely than women to have neglected their cholesterol tests (Source: AHRQ Medical Expenditure Panel Survey, 2005). Furthermore, men are 1.5 spells more likely than women to die from heart disease, cancer and chronic lower respiratory diseases (Source: Centers for Disease Control and Prevention, 2005).

The new campaign encourages men throughout 40 to learn which preventive screening tests they need to get and when they need to get them. This campaign complements AHRQ’s existing efforts toward improving the safety and quality of health care and promoting enduring involvement in their own health care, including the "Questions are the Answer" campaign launched with the Ad Council in March 2007 and the "Superheroes" Spanish-language campaign launched in March 2008.

"We hope this campaign will inform men about the importance of prevention and show them that they should work with their health care providers to find out what they should do to stay healthy," said AHRQ Director Carolyn M. Clancy, M.D.

The campaign highlights the work of the AHRQ-sponsored U.S. Preventive Services Task Force, which is an independent panel of experts in primary care and prevention that systematically reviews the evidence of effectiveness and develops recommendations for clinical preventive services. "By taking steps to prevent disease and stay strong, men can live longer and more productive lives," said Task Force Chair Ned Calonge, M.D., M.P.H. "Prevention is a decision that includes participating in regular physical activity, eating a healthy diet and finding out which preventive medical tests are right for you."

Created pro bono for the Ad Council by McCann Erickson Detroit, the public service advertising campaign includes new television, radio, print and Web advertising featuring the theme "Real Men Wear Gowns." The lighthearted ads incorporate family as a key motivating factor for men to take a more active role in preventive health. They show the target audience that being a real re-enforce means taking care of themselves (and their health) in regulate to be there for their families and in the future. Ad Council research showed this was a strong motivating factor for men.

"Our research conducted during the development of this campaign found that despite their increased health risks men aren’t taking preventive steps and are often only visiting their doctors when they experience symptoms," said Peggy Conlon, President & CEO of the Ad Council. "We are magnificent to continue our beginning with AHRQ with this wonderful succession of PSAs designed to motivate men to take a more active role in their preventive health care.

The campaign encourages men to visit a comprehensive Web seat www.ahrq.gov/realmen. The site provides the recommended ages for preventive testing (as well as a list of tests), a quiz designed to test your knowledge of preventive health care, tips for talking through your adept, a glossary of consumer freedom from disease terms, and links to online resources where you can find besides medical information.

Public service advertisements are being distributed to approximately 33,000 media stations nationwide this week. Per the Ad Council’s donated media model, all of the new public service advertisements give by will air and run in advertising time and space donated by the media.

No comments

Anticholinergic Drugs May Increase Cognitive Decline In Older People

April 22nd, 2008 | Category: Uncategorized

Anticholinergic drugs, such as medicines towards stomach cramps, ulcers, motion sickness, and urinary incontinence, may cause older people to experience greater decline in their thinking skills than people not taking the drugs.

The study looked at the furniture of taking a medication with anticholinergic properties on the annual change in thinking abilities of 870 Catholic nuns and clergy members who were an average of 75 years pristine. All of the participants were part of the Rush Religious Orders Study, an ongoing, longitudinal, clinical study of older people without dementia.

All of the participants underwent annual cognitive tests and reported their medication use for an average followup period of eight years. During the study, 679 people took at least one medication by anticholinergic properties.

The study found those people who took anticholinergic drugs saw their rate of cognitive function decline 1.5 times in the same manner with fast as those people who did not take the drugs.

“Our findings point to anticholinergic drugs having any adverse impact on cognitive performance in otherwise normal, older people,” said study author Jack Tsao, MD, DPhil, Associate Professor of Neurology at Uniformed Services University in Bethesda, Maryland, and member of the American Academy of Neurology. “Doctors may need to take this into account before prescribing these commonly used drugs.”

Tsao says more research is needed to decide the mechanism behind the rapid memory loss apparently associated with anticholinergic drugs and to identify which drugs, in particular, may be more likely to impair cognition. 

2 comments

New Tools To Improve Patient Safety During Transitions Of Care

April 22nd, 2008 | Category: Uncategorized

National Transitions of Care Coalition (NTOCC) Advisory Task Force authorized the release of recently developed tools for helping healthcare professionals and organizations address problems inherent in transitioning patients from one level of care to another. The tools describe the culmination of several months of collaboration between 29 industry stakeholders who joined together in 2006 to address challenges associated with transitions of care. In addition, NTOCC is in addition releasing accompanying information on how to implement and measure the tools as well as material designed to raise industry, policy maker, media and the general public’s awareness of transitions of care.

"The amount of labor this group has accomplished in just 18 months is impressive," Cheri Lattimer, NTOCC Project Director and CMSA Executive Director said. "For a group this large, representing such diverse points of view within healthcare, to come together and not only agree that transitions of care is a serious problem but also design, develop and launch tools to impact this issue is a wild accomplishment."

Included with the launch of the tools is a "Case Study Implementation and Evaluation plan" on how healthcare providers have power to implement them within their clinical environments viewed like well to the degree that a process for evaluating and measuring their effectiveness. "Providers can use the tools and process to start making changes in how transitions occur within their facilities," H. Edward Davidson, PharmD, MPH and the representative of the American Society of Consultant Pharmacists (ASCP) said. "The goal is that providers are empowered to take the first step at measuring their own performances in transitions of care and identify areas for improvement. These areas include such things while improving how medication changes are reconciled when patients move from a nursing home to a hospital, through the hospital, and from one side the discharge process." The materials include an educational component about transitions of care, an implementation case study and evaluation methodology.

The released tools address several important areas that impact operative and safe transitions including:

– Personal Patient "My Medicine List" Essential Data Elements: This is a list of medications to have existence carried at all times by every patient. The data elements indicate the prescriptions that patients have been prescribed and are currently taking along with information about their over-the-counter medications, vitamins, and nutritional supplements. The goal of the personal medicine list is to help patients improve their understanding of their current medicine regimens and assist healthcare providers in ensuring safe transference of medication information.

– Medication Reconciliation Essential Data Specifications: These consensus elements will help healthcare professionals collect, bear and receive critical medication information needed when patients move from one practice setting or level of care to another. The use of these elements in the reconciliation process required by the Joint Commission could help reduce medication errors.

– Elements of Excellence Transitions of caution Checklist: This list provides a detailed description of effective enduring transfer between practice settings. This process have power to help to ensure that patients and their critical medical information are transferred safely, timely, and efficiently.

In addition, NTOCC authorized the release of materials that will help the industry, consumers, government officials and regulators better understand the problems inherent in transitions of care and recommendations on how to be the occasion of better transitions. This material includes an awareness slide deck as well as a detailed concept paper outlining steps to be considered by the healthcare industry and policy makers to improve transition performance.

Transitions of care include situations in which a patient moves from primary care to specialty physicians or moves within the hospital including moves from the emergency department to other various departments, such as surgery or intensive care; or when a patient is discharged from the hospital and goes home or to an assisted living, skilled nursing resource, or hospice. Patients, especially older persons, face momentous challenges when moving from one level of care or practice setting to another in the healthcare regularity. During these transitions, lack of communication can result in redundant or conflicting information that often creates serious issues for patients, their caregivers and their families.

No comments

Dynatronics Introduces New DynaPro Spinal Health System

April 22nd, 2008 | Category: Uncategorized

Dynatronics Corporation introduced two new products: the DynaPro Spinal Health System for treating back pain and the Dynatron X5 "Turbo" soft-tissue oscillation therapy unit.

"The new DynaPro Spinal Health System uses a four-phase treatment regimen combining the benefits of decompression with light therapy, core-stabilization exercises and food," said Larry K. Beardall, executive immorality president of sales and marketing. "Decompression therapy has been shown effective in relieving pain associated with a host of back problems including herniated discs, degenerative disc disease, sciatica and pinched nerves."

In addition to offering the most comprehensive approach to the effective treatment of many of the most common causes of back and neck pain, the DynaPro Spinal Health System incorporates a state-of-the-art marketing and patient- awareness program to help practitioners promote this proven, non-surgical pain relief treatment. With Dynatronics’ revolutionary "Play Before You Pay" program, practitioners are able to "test drive" the concept by pre-marketing treatments prior to purchasing the system.

Another new product introduced this month is in addition being well received by the rehabilitation market. The new Dynatron X5 "Turbo" is three times more powerful than the original X5 device. It creates an electrostatic field within the patient that results in a highly effective treatment for acute as well as chronic pain. Soft-tissue swinging therapy has proven to be very effective in the treatment of various orthopedic and sports injuries, and is gaining popular regard in sports medicine.

"We notice immediate reductions in acute edema and joint stiffness," reported Mike Cembellin, Director of Sports Medicine, Santa Clara University. "The results from the X5 are powerful."

"We believe there is remarkable potential for both these new products," added Beardall. "The demand they will generate is expected to raise our fourth quarter results higher than previously anticipated."

Initial shipments of the new DynaPro Spinal Health System and the X5 "Turbo" have begun this month.

Dynatronics manufactures, markets and distributes advanced-technology medical devices, orthopedic soft goods and supplies, treatment tables and rehabilitation equipment for the physical therapy, pain management, sports medicine, chiropractic, podiatry, plastic surgery, dermatology and other related medical, cosmetic and aesthetic markets.

28 comments

Canada: Taking Action On Bisphenol A - Another Chemical Of Concern

April 22nd, 2008 | Category: Uncategorized

The Honourable Tony Clement, Minister of soundness, and the Honourable John Baird, Minister of the Environment, today announced that the Government is taking action to protect the health of Canadians and the environment from any other chemical of concern.

Canada is the first fatherland in the world to complete a risk assessment of bisphenol A in consultation with industry and other stakeholders, and to initiate a 60 day public comment period on whether to ban the importation, sale and advertising of polycarbonate baby bottles which contain bisphenol A.

"Canada has been the first country in the world to conduct risk assessments on a number of chemicals of concern, as a result of a new initiative announced by the Prime Minister on December 8, 2006 known as the Chemicals Management plan," said Minister Clement.  "We have immediately taken action in succession bisphenol A, because we put confidence in it is our responsibility to ensure families, Canadians and our environment are not exposed to a potentially harmful chemical."

Health Canada’s screening assessment of bisphenol A primarily focused on its impacts on newborns and infants up to 18 months of age; however, health risks for Canadians of all ages were considered in the screening.

It was determined that the main source of exposure for newborns and infants is from one side the use of polycarbonate baby bottles when they are exposed to high temperatures and the migration of bisphenol A from cans into infant formula. The scientists concluded in this assessment that bisphenol A exposure to newborns and infants is below levels that may nonplus a risk, however, the cleft between exposure and effect is not large enough.

To be wise, the Government of Canada is proposing to reduce bisphenol A exposure in infants and newborns by proposing a number of actions: to ban polycarbonate baby bottles; to develop severe migration targets for bisphenol A in infant formula cans; to work with assiduousness to develop alternative food packaging and disclose a code of practice; and to list bisphenol A under Schedule 1 of the Canadian Environmental Protection Act.

Environment Canada scientists also found that at low levels, bisphenol A can harm fish and aquatic organisms over time. Studies indicate that it can currently be found in wastewater and slush treatment plants.

"When it comes to Canada’s environment, you can’t put a price on safety," said Minister Baird. "Not only are we finding out about the health impacts of bisphenol A, but the environmental impacts as well. That’s why our Government will be moving forward and will work with the provinces and stakeholders to keep bisphenol A out of our environment, and take the necessary measures to ensure its undamaged use and disposal."

31 comments

Overuse Of Codeine, Oxycodone, Barbiturates Increases Risk Of Chronic Migraine

April 22nd, 2008 | Category: Uncategorized

People who overuse barbiturates and opioids, such as codeine, butalbital, and oxycodone, to treat migraine are at an increased risk of developing deep-seated migraine.

For the study, 24,000 people by headaches in the United States were surveyed about the types of medications they use to treat their headaches. From this sample of people with headache, the researchers selected those who had been diagnosed in 2005 with episodic migraine (fewer than 15 days of headache per month). Their risk of chronic migraine was then calculated based on the types of medications they used in 2005. Among those with episodic migraine in 2005, 209 people had developed chronic migraine in 2006.

The study found people who took drugs containing barbiturates or opioids for only eight days a month were twice similar to likely to develop inveterate migraine a year later as those who didn’t take such drugs.

“People who use drugs that contain barbiturates and opioids, if only for a total of seven to eight days a month, appear to significantly increase their risk of migraine progression,” said study author Marcelo Bigal, MD, PhD, with Albert Einstein College of Medicine in Bronx, New York. “Strict limits for these types of drugs should be enforced among people with migraine as a way of preventing their migraines from becoming more frequent and more painful.”

The study found no evidence that the risk of developing chronic migraine increased among people who frequently used triptans, which are commonly prescribed drugs to treat migraine, or non-steroidal antiinflammatory drugs (NSAIDs), such as aspirin, ibuprofen and naproxen. 

2 comments

Keep An Eye On Allergies This Season

April 22nd, 2008 | Category: Uncategorized

An estimated 50 million Americans suffer from the miseries of allergies, by allergic reactions involving the eyes a for the sake of the use of all complaint. For many, symptoms of eye allergies can be so uncomfortable and irritating that they interfere with job performance, impede leisure-time and sports activities, and curtail vacations.

To help allergy sufferers better understand and manage the condition, the asthma and Allergy Foundation of America (AAFA), the leading patient organization for people with asthma and allergies, is offering a free educational brochure titled "Eye Health and Allergies."

"Approximately four percent of allergy sufferers experience observe allergies as their primary allergy, oftentimes caused by many of the same triggers as indoor/outdoor allergies such as pollen, mold, or pet dander," says Mike Tringale, Director of External Affairs, AAFA. "This brochure offers useful information on how eye allergies occur, common signs and symptoms, and practical advice on how to treat and preclude eye allergies."

The brochure, supported by 1-DAY ACUVUE MOIST Brand Contact Lenses, also includes smart allergy season strategies for the nation’s 40 million contact lens wearers, a group for whom fix the eye on allergies can use unique problems.

"Allergy sufferers who wear contact lenses that you use for two weeks or more may experience discomfort and symptoms such as ocular itching, tearing, and redness, because allergens and other irritants can build up on the lenses over time, explains New York-based Optometrist Susan Resnick, O.D., F.A.A.O. "Chemical disinfectants and preservatives used in some contact lens care systems also can cause ocular distress."

To help minimize these symptoms, contact lens wearers can limit their wearing time during allergy season, but Dr. Resnick says there is no need to put an end to contact lens wear for the period of the allergy season.

"Studies have shown that single use contacts — daily disposable lenses that you throw away at the end of the day — can be a healthy and more comfortable option for many people with eye allergies," she notes. "By putting in a with ceremonial, fresh lens every time, one-day contacts minimize the potential for accumulation of allergens and irritants that can often accumulate with repeated use of the same span of lenses."

In a three-year investigate comparing the clinical performance of daily disposables (1-DAY ACUVUE Brand Contact Lenses) with that of conventional daily-wear lenses, single-use lens wearers reported fewer symptoms of redness, cloudy vision, and grittiness; at the same time, they reported better vision and overall satisfaction, and had fewer lens external part deposits, complications, or unscheduled doctor’s visits.

2 comments

Boston Scientific Receives Approval For TAXUS Liberte Stent System

April 22nd, 2008 | Category: Uncategorized

Boston Scientific Corporation has received approval for the sale of its TAXUS Liberte paclitaxel-eluting coronary stent system in Canada. The Company reported that Health Canada’s Therapeutic Products Directorate (TPD), the authority that regulates pharmaceutical drugs and of the healing art devices, has approved its use. The Company said it plans to launch the product immediately in Canada.

"The TAXUS Liberte Stent is a major advance in stent development and raises the bar for drug-eluting stent systems," said Serge Doucet, M.D., Cathlab Director at the Montreal Heart Institute. "It offers enhanced ability to conform to the vessel wall and deliver across some of the most challenging lesions. This innovation is welcome word for interventional cardiologists and patients in Canada who suffer from coronary artery disease."

"This stent is designed specifically for improved drug elution and deliverability," said David McFaul, Boston Scientific Senior Vice President, International. "Coupled with our proven paclitaxel-eluting technology, TAXUS Liberte provides physicians with next-generation performance. We are delighted that Canadian physicians and patients can now benefit from this highly advanced technology for the treatment of coronary artery disease."

Currently the leading drug-eluting stents worldwide, TAXUS Stent Systems have been evaluated by the industry’s most extensive randomized, controlled clinical trial program, as well as studied in more than 35,000 real-world patients enrolled in post-approval registries. To date, approximately four the multitude TAXUS Stents have been implanted worldwide.

The TAXUS Liberte Stent has previously been approved for sale in Europe and other international markets and is currently awaiting approval by the U.S. Food and Drug Administration and is not available for sale in the United States.

34 comments

U.S. And China At Loggerheads Over Contaminated Heparin

April 22nd, 2008 | Category: Uncategorized

Health officials in the U.S. appear to be at loggerheads through Chinese officials over the infection of the blood-thinning drug Heparin.

According to the Food and Drug Administration (FDA) they have new evidence linking a contaminant to deaths and allergic reactions in patients who took the blood-thinner Heparin which were made with ingredients from China.

The adverse events have included allergic or hypersensitivity-type reactions, with symptoms such as low blood pressure, shortness of breath, nausea, vomiting, diarrhea and abdominal pain.

Chinese officials have rejected the allegations and say that the chemical concerned was not the culprit.

The FDA says new data from inquiry showed the contaminant, over-sulfated chondroitin sulfate, could trigger side effects such as those reported in the deaths of 81 Heparin patients.

In February this year drug company Baxter International was forced to recall most of its Heparin products made with ingredients from China following five deaths which were suspected to be linked to the chemical which originated from China.

Chinese officials maintain tests on batches of Heparin used by a patient who reported health problems, showed only some contained the contaminant.

The deputy director-general of the China National Institute for the Control of Pharmaceutical and Biological Products, Jin Shaohong says this shows that over-sulfated chondroitin can therefore not be the suspected cause of the Heparin linked adverse events.

However FDA officials insist they tested the Heparin in question and found the contaminant, and what is more ten other countries had furthermore detected over-sulfated chondroitin sulfate in samples of Heparin made with Chinese ingredients; they are Australia, Canada, China, Denmark, France, Germany, Italy, Japan, The Netherlands, New Zealand.

The FDA says of all the contaminated Heparin found around the world, the one thing they have in common is China.

According to Chinese officials other contaminants could be to blame such as problems with the device used to inject the drug, or health factors with the patients who used the drug.

While Chinese investigators are calling for more information on the patients involved, Baxter has get to down upon the side of the FDA and says its own testing had also shown that over-sulfated chondroitin sulfate could cause the token of reactions reported in Heparin patients.

Baxter says the contaminant is the likely cause of the increased adverse reactions to the Heparin.

Heparin is made from pig intestines and is often collected from small and adhering the whole, unregulated farms in China; Baxter believes the contamination occurred before the product reached Baxter or its raw ingredient supplier.

An FDA investigation in both the United States and abroad included inspecting Baxter’s domestic facilities, examining Heparin products in the United States and sending a team of experts to China to conduct a comprehensive inspection of the Changzhou SPL facility that makes the active ingredient for the drug.

The FDA says at this point it is unclear how the Heparin-like compound got into the Heparin Active Pharmaceutical Ingredient, but they are continuing to investigate the place.

The FDA has issued a warning to the Chinese supplier of in the natural state Heparin for Baxter, for failing to ensure its manufacturing process removes impurities.

The supplier Changzhou SPL says it will cooperate with the agency.

Allergic reactions, or low blood pressure, have also been reported after patients received Heparin, including Baxter’s product.

The drug Heparin is used in kidney dialysis and various surgeries to prevent blood clots, and allergic reactions, or low blood pressure, have likewise been reported following patients receiving Heparin.

The FDA says that the Heparin currently sold in the United States was being tested and was safe and the recent increase in Heparin reactions were only reported in Germany and the United States.

The Heparin scare is just the latest in a succession of recalls involving products from China, including contaminated pet food, excessive lead in paint on toys and anti-freeze in toothpaste.

Health and Human Services Secretary Michael Leavitt says just sending inspectors to China and other countries will not be enough to make sure food and drugs are safe.

Leavitt suggests that independent certification may be the best solution and with that in mind the U.S. is considering setting up an office to strengthen oversight of food, drugs and devices imported from China.

Leavitt however believes that ultimately regulation will not be the answer and he has called for a new industry of global independent certification of farms, factories and other producers.

2 comments

FDA says Pfizer’s online Viagra ad did not mention risks (AP)

April 22nd, 2008 | Category: Uncategorized

WASHINGTON - Federal regulators have warned Pfizer Inc. for not mentioning the risks of viagra in an advertisement featuring country musicians singing the praises of its popular impotency pill.

The Food and Drug Administration called on Pfizer to discontinue the online video advertisement in a warning letter issued extreme week and posted online Monday.

The 30-second video, which appeared on CNN.com, showed a group of Nashville musicians singing the refrain “Viva Viagra” in a song here and there the benefits of the drug.

Pfizer said in a statement that a technical number with CNN’s Web site prevented the risk information from displaying forward a banner accompanying the video and that it has since pulled the ad.

“Pfizer discovered the error, notified the Web site of the error, and our understanding was that the Web locality corrected its error immediately,” the New York-based company said in a statement.

Drugmakers are required to mention a drug’s negative side effects in any advertisement that highlights benefits. Viagra’s label warns of potential risks to patients with existing heart conditions during the time that well as reported headaches and abnormal vision.

In its warning letter, the FDA said the ad “raises public health and safety concerns through its complete omission of risk complaint for Viagra.”

Shares of Pfizer Inc. fell 33 cents Tuesday to $20.14 in afternoon trading.

4 comments

FDA objects to online ad for Pfizer’s Viagra (Reuters)

April 22nd, 2008 | Category: Uncategorized

WASHINGTON (Reuters) - An online advertisement by men praising Viagra to the tune of an Elvis Presley song has drawn objections from U.S. regulators, who said drugmaker Pfizer Inc failed to list the impotence drug's risks.

Pfizer said the failure of side effects warnings was due to a technical error on CNN's Web site, http://www.cnn.com, which ran the advertisement.

The Food and Drug Administration sent a written warning to Pfizer that was made public on Monday.

"The video raises public health and safety concerns through its complete omission of risk information for Viagra by suggesting that Viagra is safer than has been demonstrated," the FDA said in its letter, dated April 16.

Viagra's prescribing instructions warn against use through men taking heart drugs known as nitrates and caution about sudden vision and hearing loss and other problems.

Pfizer spokesman Francisco Gebauer said the expose to danger information should have appeared simultaneously in print on the computer screen. The information did not run "owed to a technical error" on the Web site of CNN, a unit of Time Warner Inc, Gebauer said.

"We regret that the Internet video ran without the appropriate preservation complaint," he said.

CNN spokesman Sal Petruzzi said the company's Web site had a "technical mishap" that was corrected.+

To avoid homogeneous errors, Pfizer has pulled all 30-second Internet video ads that require safety information to appear separately on the screen moderately than within the advertisement, Gebauer said.

viagra's worldwide sales were nearly $1.8 billion in 2007. The drug's generic name is sildenafil.

(Reporting by Lisa Richwine)

3 comments